3.51
-0.18 (-4.88%)
| Penutupan Terdahulu | 3.69 |
| Buka | 3.71 |
| Jumlah Dagangan | 13,698 |
| Purata Dagangan (3B) | 22,864 |
| Modal Pasaran | 1,884,600 |
| Harga / Buku (P/B) | 0.330 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Mar 2025 - 31 Mar 2025 |
| EPS Cair (TTM) | -105.78 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.74% |
| Nisbah Semasa (MRQ) | 6.10 |
| Aliran Tunai Operasi (OCF TTM) | -8.06 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.56 M |
| Pulangan Atas Aset (ROA TTM) | -62.40% |
| Pulangan Atas Ekuiti (ROE TTM) | -149.45% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Bercampur |
| Diagnostics & Research (Global) | Bercampur | Bercampur | |
| Stok | ENDRA Life Sciences Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -2.0 |
| Purata | -0.17 |
|
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.14% |
| % Dimiliki oleh Institusi | 0.02% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 31 Mar 2025 | Pengumuman | ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies |
| 31 Mar 2025 | Pengumuman | ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |